June 29, 2026
MSCopilot® interim results at EAN 2026
At the 12th Congress of the European Academy of Neurology (#EAN2026) in Geneva, we are proud to present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies (conducted with the support of Sanofi).
These follow-up data confirm that MSCopilot® is a reliable tool for evaluating multiple sclerosis over the long term, both in everyday care and during clinical trials.
MS-DETECT: Validation of long-term clinical accuracy
For the first time, evidence of a consistent one-year correlation between MSCopilot® digital tests and reference scores (MSFC). A strong correlation confirming its reliability for precisely tracking disease progression.
MS-FLOWER: Accelerating real-world deployment
Analysis of potential barriers to clinical adoption through a pilot study in 4 US centers. The objective: to accelerate the integration of MSCopilot® into routine care in Europe and the United States.